IMMUNOLOGICAL MECHANISMS INVOLVED IN PSORIASIS DEVELOPMENT
Article Sidebar
Main Article Content
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by abnormal keratinocyte proliferation and persistent inflammation. Recent advances in immunology have demonstrated that immune system dysregulation plays a fundamental role in the initiation and progression of psoriasis. This article aims to analyze and summarize the key immunological mechanisms involved in psoriasis development, with a particular focus on the interaction between innate and adaptive immune responses. A narrative and analytical review of scientific literature published between 2010 and 2024 was conducted using major international databases. The findings indicate that dendritic cells, T lymphocytes—especially Th17 and Th1 subsets—and keratinocytes are central contributors to psoriatic inflammation. The IL-23/Th17 axis was identified as the dominant pathogenic pathway, while proinflammatory cytokines such as IL-17, IL-22, TNF-α, and IFN-γ play crucial roles in sustaining chronic inflammation. Understanding these immunological pathways has led to the development of targeted biologic therapies and has significantly improved disease management. A deeper insight into immune-mediated mechanisms may further enhance personalized treatment strategies and long-term clinical outcomes for patients with psoriasis.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
2.Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
3.Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315.
4.Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
5.Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354.
6.Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
7.Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945–1960.
8.Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150.